NASDAQ$AVIR
Atea Pharmaceuticals Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Atea Pharmaceuticals reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
Atea Pharmaceuticals reported fourth quarter collaboration revenue of $192.2 million and net income of $117.1 million. The company is advancing three Phase 2 programs in COVID-19, HCV, and dengue fever.
- Priority is to develop a combination regimen with bemnifosbuvir and a protease inhibitor for COVID-19.
- Initiating Phase 2 combination clinical trial of bemnifosbuvir and ruzasvir (RZR) as potential best-in-class pan genotypic regimen for hepatitis C virus (HCV) in 2H 2022.
- Advancing AT-752 as a potential first antiviral treatment for dengue fever in Phase 2 program in 1H 2022.
- Strategic collaboration with Roche was terminated, giving Atea full rights to continue clinical development and commercialization of bemnifosbuvir worldwide.
Headline financials
Revenue & EPS history
Atea · Revenue · Quarterly
$192M
Forward guidance
Atea anticipates several important milestones and data readouts from its programs during the year and has the financial strength and a seasoned management team to advance these programs through key clinical and regulatory inflection points.
Tailwinds
- Meaningful progress advancing three Phase 2 programs in COVID-19, HCV and dengue fever during 2022
- Combination therapies will be needed to treat broader patient populations, as new COVID-19 variants occur, and viral drug resistance will likely emerge to protease inhibitor monotherapy.
- Combination of RZR and bemnifosbuvir has the potential to be a best-in-class pan-genotypic combination regimen to help fight the increase in HCV infections caused by the opioid crisis, IV drug use and HCV reinfection
- Making significant progress advancing AT-752 as a potential first antiviral treatment for dengue fever, the most prevalent mosquito-borne viral disease with a large global disease burden.
- Initiate a Phase 2 clinical trial in dengue endemic countries and a human challenge study in the U.S. during the first half of 2022 and expects to report results from these studies in late 2022.
Headwinds
- Uncertainty around and costs associated with the development of AT-752 as a potential treatment for dengue and combination product candidates including bemnifosbuvir for the potential treatment for COVID-19 and HCV
- Dependence on management, directors and other key personnel
- Impact of the COVID-19 pandemic on our business
- Limited operating history and no history of successfully developing or commercializing any products, significant operating expenses since inception
- Need for substantial additional funding
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+0.1%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.2%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+16.1%
Q1 2021
Best reaction
-16.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2025 | +11.1% | +15.1% | +8.7% | |
| Q3 2025 | -12.1% | -12.9% | -10.0% | |
| Q2 2025 | -2.6% | +1.2% | -2.6% | |
| Q1 2025 | +2.2% | +4.0% | +16.4% | |
| Q4 2024 | -0.3% | +3.3% | -7.0% | |
| Q3 2024 | -2.2% | -7.0% | -17.9% | |
| Q1 2024 | -8.2% | -9.7% | -8.4% | |
| Q4 2023 | -5.5% | -11.4% | -11.4% | |
| Q3 2023 | -10.7% | -14.0% | -10.1% | |
| Q2 2023 | +4.1% | +0.3% | -3.5% | |
| Q1 2023 | -1.2% | -3.0% | +35.8% | |
| Q4 2022 | -8.7% | -0.8% | -8.1% | |
| Q3 2022 | -12.4% | -14.4% | -24.0% | |
| Q2 2022 | -3.5% | -4.3% | -11.7% | |
| Q1 2022 | +12.9% | +36.8% | +52.7% | |
| Q4 2021 | +1.4% | -9.7% | +11.1% | |
| Q3 2021 | +6.5% | +6.5% | -25.3% | |
| Q2 2021 | -16.2% | -12.9% | -13.4% | |
| Q1 2021 | +16.1% | +18.7% | +20.4% | |
| Q2 2020 | +5.3% | -1.4% | -55.0% | |
| Q4 2020 | +5.3% | -1.4% | -55.0% | |
| Q1 2020 | +7.2% | +10.6% | +73.1% | |
| Q4 2019 | +7.2% | +10.6% | +73.1% | |
| Q3 2020 | +7.2% | +10.6% | +73.1% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro